Business, energy, technology, markets and global industry news from Business News Today

major depressive disorder

PharmaDeviceNews major depressive disorder
Pharma & Biotech

What does the PIPE-307 MOONLIGHT-1 miss mean for Contineum Therapeutics stock?

Contineum shares face pressure after Johnson & Johnson’s PIPE-307 misses its Phase 2 depression endpoint, shifting attention to PIPE-791.

Read More
Helus Pharma’s HLP003 moves closer to a pivotal Phase 3 depression data readout after the APPROACH study completed enrolment ahead of schedule. Representative image.
Pharma & Biotech

Helus Pharma finished Phase 3 enrolment early, but HLP003’s decisive test is still ahead

Helus Pharma completes APPROACH enrolment as HLP003 heads toward a pivotal Phase 3 depression data readout in the fourth quarter of 2026.

Read More
Robotic transcranial magnetic stimulation technology positions a TMS coil near a patient’s head, illustrating the clinical workflow behind Zeta Surgical’s FDA-cleared robotic TMS system. Representative image.
Medical Devices & Diagnostics

FDA clears Zeta’s robotic TMS system, but the real test begins inside busy clinics

Zeta Surgical wins FDA clearance for its robotic TMS system, advancing automated coil positioning and motion compensation in neuromodulation clinics.

Read More
Representative image: Definium Therapeutics’ $805 million public offering strengthens its ability to advance DT120 ODT after positive Phase 3 depression trial results, while regulatory and commercial execution remain the next major tests.
Pharma & Biotech

DT120 delivered a Phase 3 surprise. Can Definium Therapeutics turn $805m into a launch?

Definium Therapeutics has used the strong market response to its DT120 ODT depression data to secure one of the largest recent biotechnology financings, giving the psychiatric drug developer substantial resources for additional trials, regulatory work and potential commercialisation.

Read More
Representative image of an outpatient neurostimulation treatment session, reflecting HOPE Therapeutics’ use of Zeta Surgical’s FDA-cleared TMS navigation system and the growing role of AI-guided precision psychiatry in treatment-resistant depression care.
Pharma & Biotech

Why HOPE Therapeutics’ first Zeta-guided TMS patients matter for psychiatry care

NRx’s HOPE Therapeutics begins Zeta-guided TMS treatments, bringing AI-powered image guidance into outpatient depression care workflows.

Read More
A clinician monitors a supervised treatment session as Definium Therapeutics advances DT120, a single-dose investigational therapy for major depressive disorder, following positive Phase 3 results. Representative image.
Pharma & Biotech

Can Definium turn a 50% stock surge into an FDA path for single-dose depression therapy?

DT120 produced a striking Phase 3 antidepressant effect after one supervised dose, but confirmation, functional unblinding, controlled-substance rules and treatment-site economics remain decisive.

Read More
Representative image: Definium Therapeutics’ DT120 ODT Phase 3 Emerge study highlights the growing focus on psychedelic psychiatry and new treatment approaches for major depressive disorder.
Pharma & Biotech

Definium Therapeutics nears pivotal MDD test as DT120 ODT faces Phase 3 scrutiny

Find out how Definium Therapeutics’ DT120 ODT Phase 3 MDD readout could reshape psychedelic psychiatry and depression drug development.

Read More
Representative image of neuropsychiatry drug research, highlighting Draig Therapeutics’ DT-101 Phase 1 data, AMPA receptor potentiation and the search for new major depressive disorder treatments.
Pharma & Biotech

Draig Therapeutics DT-101 Phase 1 data put MEG biomarkers at the centre of depression trials

DT-101 may revive AMPA receptor depression research, but Phase 2 must prove safety signals can become real clinical benefit.

Read More
Pharma & Biotech

Autobahn’s elunetirom Fast Track win puts bipolar depression back in regulatory focus

Bipolar depression needs better options. Autobahn’s elunetirom Fast Track status raises the stakes for its Phase 2 readout.

Read More
Pharma & Biotech

Is lysergide finally going mainstream? Definium Therapeutics bets on DT120 ODT clinical momentum

Can DT120 ODT transform mental health treatment? Explore Definium Therapeutics’ pivotal trials and what they mean for psychedelic psychiatry.

Read More